Molecular Imaging 2017

Risk consideration: out field recurrence vs. local control

>> 50% risk of local progression in advanced NSCLC

possible improvement by dose escalation

must be weighed against

< 10% residual risk of out field recurrence from microscopic nodal spread if no ENI

→ Clinical studies!

Slide 23

Saunders R&O 1999